Outsourcing in Clinical Trials Europe 201421-22 May 2014, Brussels, Belgium
With the Pharma/ Biotech industry growing year on year and the degree of outsourcing within clinical trials growing significantly, there comes a host of new challenges for pharmaceutical and biotech companies and it has never been more important to ensure that vendors are used to their maximum ability and at minimal cost.
This event will bring together senior industry representatives to discuss the latest challenges within clinical outsourcing such as vendor sourcing, selection and contracting, as well as communication, oversight and management. Outsourcing in Clinical Trials Europe will present itself as a unique forum for discussion and idea-sharing on innovative strategies within outsourcing models in this ever-growing region.
What benefits can outsourcing your clinical trials bring to your business?
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Analysing both pre and post partnerships to enhance your strategy and make it fit for purpose
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
Pfizer has released top-line results from two major Phase III trials from the Oral treatment Psoriasis Trials (OPT) Programme, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), of tofacitinib, the first in a new class of medicines, to treat pa…
Cubist Pharmaceuticals has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for its investigational antibiotic, ceftolozane/tazobactam for the treatment of complicated urinary tract infections (cUTI) and complicated i…
US-based biopharmaceutical firm Questcor Pharmaceuticals has reported results from an investigator-initiated clinical trial evaluating the dosing and effectiveness of HP Acthar Gel (repository corticotropin) in 20 patients with nephrotic syndrome due…
US-based VentiRx Pharmaceuticals has announced the completion of patient enrollment in GOG-3003, a Phase II study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallo…
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally …